Purple Biotech CEO Gil Efron to Step Down in August 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Mar 13 2026

0mins

PPBT-1.37%

Should l Buy PPBT?

Source: seekingalpha

Executive Transition: Purple Biotech announced that CEO Gil Efron will step down in August 2026, marking the end of his eight-year tenure in senior leadership roles, including Chief Financial Officer and CEO, indicating a significant shift in the company's leadership structure.
Leadership Experience: Efron has served as CEO since 2022, during which the company underwent several strategic adjustments; while specific performance metrics are not disclosed, his decisions will have lasting implications for the company's future trajectory.
Market Reaction: This announcement may raise investor concerns regarding the company's future direction, particularly during the leadership transition, which could impact stock prices and market confidence, necessitating close monitoring of subsequent leadership selection.
Strategic Planning: Purple Biotech must establish a clear succession plan following Efron's departure to ensure continuity and stability in its strategic initiatives, mitigating potential disruptions to business operations due to leadership changes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PPBT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PPBT

Wall Street analysts forecast PPBT stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.910

Low

34.00

Averages

34.00

High

34.00

Current: 3.910

Low

34.00

Averages

34.00

High

34.00

H.C. Wainwright

Emily Bodnar

Buy

downgrade

$34 -> $30

2026-03-13

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$34 -> $30

AI Analysis

2026-03-13

downgrade

Buy

Reason

H.C. Wainwright analyst Emily Bodnar lowered the firm's price target on Purple Biotech to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 earnings and provided a corporate update, highlighting recent progress for the company's preclinical CAPTN-3 tri-specific T cell engager programs, the analyst tells investors in a research note. The firm said it expects additional updates regarding progress of the investigational new drug submission and plans for Phase 1 throughout 2026. The firm added that its new price target is based on a discounted cash flow analysis.

About PPBT

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM

Apr 23 2026moomoo

New Advisory Board Established: Purple Biotech Ltd has formed a scientific advisory board for its CAPT-N-3 antibody platform.
Focus on Antibody Development: The board will provide expertise and guidance to enhance the development of the CAPT-N-3 antibody platform.

Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI

Mar 25 2026moomoo

Collaboration Announcement: Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform.
Focus on Accelerated Development: The partnership aims to accelerate the development process of innovative therapeutic solutions using advanced antibody technology.

Purple Biotech Regains Nasdaq Compliance

Mar 17 2026seekingalpha

Compliance Restoration: Purple Biotech confirmed on March 13, 2026, that it has regained compliance with Nasdaq rules, maintaining a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days, ensuring its continued listing on the Nasdaq Capital Market.
Market Reaction: This compliance restoration may boost investor confidence and improve the company's stock performance, especially after facing compliance risks, potentially enhancing market expectations for its future development.
Financial Performance: Purple Biotech reported a Non-GAAP EPS of $19.85, indicating strong profitability, which further solidifies its market position in the biotechnology sector.
Future Outlook: With compliance issues resolved, Purple Biotech can focus more on its R&D and market expansion strategies, which is expected to drive long-term growth potential in the biopharmaceutical industry.

Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses

Mar 13 2026seekingalpha

Widening Financial Losses: Purple Biotech reported an operating loss of $23.4 million in Q4, an increase of $22.4 million compared to the same period in 2024, primarily due to $20.5 million in non-cash impairment expenses recognized during the period, indicating significant R&D expenditures.
Adjusted Operating Loss: The adjusted operating loss was $2.9 million, up from $1.0 million in the same period of 2024, primarily reflecting increased activities in the CAPTN-3 platform development, showcasing the company's ongoing investment in new product development.
Significant Net Loss: The net loss reached $23.6 million, a substantial increase of $23.1 million compared to $0.4 million in 2024, largely driven by the $20.5 million non-cash impairment expenses, highlighting the growing financial pressures faced by the company.
Cash Flow Status: As of December 31, 2025, Purple Biotech had cash and cash equivalents totaling $9.5 million, which is expected to provide a cash runway into 2027, despite ongoing financial challenges.